The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
 
Cecile Vicier
Travel, Accommodations, Expenses - Chugai Pharma Europe; Pfizer
 
Wanling Xie
Consulting or Advisory Role - Bayer
 
Anis Hamid
Honoraria - Bayer
Speakers' Bureau - Bayer
Travel, Accommodations, Expenses - AMGEN
 
Carolyn Evan
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Genentech/Roche; Janssen Biotech; Pfizer; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen Biotech (Inst); Sanofi (Inst); Sotio (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination